University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Emmanuelle Waubant

Emmanuelle Waubant, Ph.D., M.D.

Neurologist

Dr. Emmanuelle Waubant is a neurologist and specialist in the treatment of patients with multiple sclerosis (MS). A native of France, she earned her medical degree at the University of Medicine in Lille, France, and completed her residency and chief residency at Toulouse University Hospital. Waubant completed fellowships in neuroimmunology at UCSF Medical Center and in clinical neuroimmunology at UCSF's Multiple Sclerosis Center at Mount Zion. She then returned to France to head a clinical research center at the Pitie-Salpetriere University Hospital. After returning to UCSF, she joined the staff of UCSF's Multiple Sclerosis Center and is an assistant professor in neurology.

Clinics

Multiple Sclerosis Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2069
Fax: (415) 353-2633

Hours: Monday to Friday
8:30 a.m. – 4:30 p.m.

Conditions & Treatments

More about Emmanuelle Waubant

Additional Languages

French

Education

University of Medicine, Lille, France 1992

Residencies

Purpan University Hospital, Neurology 1992

Fellowships

UCSF Medical Center, Neurology 1999

Selected Research and Publications

  1. Waubant E, Cross A. MS and related disorders: groundbreaking news. Lancet Neurol. 2014 Jan; 13(1):11-3.
  2. Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, Malikova I, Roger E, Kinkel RP, McDonald J, Bacchetti P, Waubant E. Association of multiple sclerosis susceptibility variants and early attack location in the CNS. PLoS One. 2013; 8(10):e75565.
  3. Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, Malikova I, Roger E, Kinkel RP, McDonald J, Bacchetti P, Waubant E. Multiple sclerosis susceptibility genes: associations with relapse severity and recovery. PLoS One. 2013; 8(10):e75416.
  4. Maghzi AH, Minagar A, Waubant E. Neuroprotection in multiple sclerosis: a therapeutic approach. CNS Drugs. 2013 Oct; 27(10):799-815.
  5. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One. 2013; 8(7):e66308.
  6. Van Haren K, Waubant E. Therapeutic advances in pediatric multiple sclerosis. J Pediatr. 2013 Sep; 163(3):631-7.
  7. Marcus JF, Waubant EL. Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. Neurohospitalist. 2013 Apr; 3(2):65-80.
  8. Chitnis T, Tardieu M, Amato MP, Banwell B, Bar-Or A, Ghezzi A, Kornberg A, Krupp LB, Pohl D, Rostasy K, Tenembaum S, Waubant E, Wassmer E. International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology. 2013 Mar 19; 80(12):1161-8.
  9. Lulu S, Waubant E. Humoral-targeted immunotherapies in multiple sclerosis. Neurotherapeutics. 2013 Jan; 10(1):34-43.
  10. McElroy JP, Krupp LB, Johnson BA, McCauley JL, Qi Z, Caillier SJ, Gourraud PA, Yu J, Nathanson L, Belman AL, Hauser SL, Waubant E, Hedges DJ, Oksenberg JR. Copy number variation in pediatric multiple sclerosis. Mult Scler. 2013 Jul; 19(8):1014-21.
  11. Waubant E, Mowry EM, Krupp L, Chitnis T, Yeh EA, Kuntz N, Ness J, Belman A, Milazzo M, Gorman M, Weinstock-Guttman B, Rodriguez M, James JA. Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Mult Scler. 2013 Jun; 19(7):891-5.
  12. Julian L, Serafin D, Charvet L, Ackerson J, Benedict R, Braaten E, Brown T, O'Donnell E, Parrish J, Preston T, Zaccariello M, Belman A, Chitnis T, Gorman M, Ness J, Patterson M, Rodriguez M, Waubant E, Weinstock-Guttman B, Yeh A, Krupp LB. Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol. 2013 Jan; 28(1):102-7.
  13. Waubant E. Improving outcomes in multiple sclerosis through early diagnosis and effective management. Prim Care Companion CNS Disord. 2012; 14(5).
  14. Zhang J, Waubant E, Cutter G, Wolinsky JS, Glanzman R. EDSS variability before randomization may limit treatment discovery in primary progressive MS. Mult Scler. 2013 May; 19(6):775-81.
  15. Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, Gourraud PA, Brenneman D, Owen MC, Qualley P, Bucci M, Hauser SL, Pelletier D. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012 Aug; 72(2):234-40.
  16. Cross AH, Waubant E. Antibodies to potassium channels in multiple sclerosis. N Engl J Med. 2012 Jul 12; 367(2):172-4.
  17. Waubant E. Overview of treatment options in multiple sclerosis. J Clin Psychiatry. 2012 Jun; 73(6):e22.
  18. Waubant E. Early recognition and diagnosis of multiple sclerosis. J Clin Psychiatry. 2012 Apr; 73(4):e14.
  19. Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology. 2012 Apr 10; 78(15):1171-8.
  20. Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler. 2012 Jul; 18(7):932-46.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2014 The Regents of The University of California